Author: Le, Michelle; Berman-Rosa, Melissa; Ghazawi, Feras M.; Bourcier, Marc; Fiorillo, Loretta; Gooderham, Melinda; Guenther, Lyn; Hanna, Sameh; Hong, H. Chih-Ho; Landells, Ian; Lansang, Perla; Marcoux, Danielle; Wiseman, Marni C.; Yeung, Jensen; Lynde, Charles; Litvinov, Ivan V.
Title: Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis Cord-id: ql6q54fn Document date: 2021_9_1
ID: ql6q54fn
Snippet: Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-severe atopic dermatitis (AD). Objective: To review the efficacy, safety, and pharmacokinetic characteristics of oral JAKi in the treatment of AD. Methods: A PRISMA systematic review was conducted using M
Document: Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-severe atopic dermatitis (AD). Objective: To review the efficacy, safety, and pharmacokinetic characteristics of oral JAKi in the treatment of AD. Methods: A PRISMA systematic review was conducted using MEDLINE, EMBASE (Ovid), and PubMed databases for studies assessing the efficacy, safety, and/or pharmacokinetic properties of oral forms of JAKi in the treatment of AD in pediatric or adult populations from inception to June 2021. Results: 496 papers were reviewed. Of 28 articles that underwent full text screening, 11 met our inclusion criteria for final qualitative review. Four studies examined abrocitinib; three studies examined baricitinib; three examined upadacitinib and one examined gusacitinib (ASN002). Significant clinical efficacy and a reassuring safety profile was reported for all JAKi agents reviewed. Rapid symptom control was reported for abrocitinib, baricitinib and upadacitinib. Limitations: Given the relatively limited evidence for each JAKi and the differences in patient eligibility criteria between studies, the data was not deemed suitable for a meta-analysis at this time. Conclusion: Given their ability to achieve rapid symptom control with a reassuring safety profile, we recommend considering the use of JAKi as a reliable systemic treatment option for adult patients with moderate-to-severe AD, who are unresponsive to topical or skin directed treatments.
Search related documents:
Co phrase search for related documents- abdominal pain and activated stat: 1
- abdominal pain and active surveillance: 1
- abdominal pain and acute pancreatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
- abdominal pain and long distance: 1
- abdominal pain and long term safety: 1, 2
- abdominal pain and long term study: 1, 2, 3, 4, 5
- abdominal pain and long term treatment: 1, 2, 3, 4
- abdominal pain and low density: 1, 2
- abdominal pain and low density lipoprotein: 1
- abdominal pain and low lymphocyte count: 1, 2
- abdominal pain and lung cancer: 1
- abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and lymphopenia patient: 1
Co phrase search for related documents, hyperlinks ordered by date